Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice

References

• Marzano AV, Pigatto P, Cristaudo A. Management of chronic spontaneous urticaria: practical parameters. G Ital Dermatol Venereol. 2015;150:237–246.25714626
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R. The EAACI/GA 2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887. doi:10.1111/all.1246224785199
   PubMed Web of Science ®Google Scholar
• Balp -M-M, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient - Patient-Centered Outcomes Res. 2015;8:551–558. doi:10.1007/s40271-015-0145-9
   Web of Science ®Google Scholar
• Maurer M, Ma D, Wei JF, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy. 2011;66:317–330. doi:10.1111/j.1398-9995.2011.02683.x21083565
   PubMed Web of Science ®Google Scholar
• Maurer M, Church MK, Marsland AM, et al. Questions and answers in chronic urticaria: where do we stand and where do we go? J Eur Acad Dermatol Venereol. 2016;30:7–15. doi:10.1111/jdv.13695
   PubMed Web of Science ®Google Scholar
• Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154:294–298. doi:10.1111/bjd.2006.154.issue-216433799
   PubMed Web of Science ®Google Scholar
• Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31:1056–1063. doi:10.1111/jdv.2017.31.issue-627911016
   PubMed Web of Science ®Google Scholar
• Greaves MW. Chronic Urticaria. N Engl J Med. 1995;332:1767–1772. doi:10.1056/NEJM1995062933226087760895
   PubMed Web of Science ®Google Scholar
• Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45:47–62. doi:10.1007/s12016-012-8326-y22674016
   PubMed Web of Science ®Google Scholar
• Beck L, Bernstein J, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017;97::149–158. doi:10.2340/00015555-2496
   PubMed Web of Science ®Google Scholar
• Chang TW, Chen C, Lin CJ. The potential pharmacologic mechanisms of Omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337–342. doi:10.1016/j.jaci.2014.04.03624948369
   PubMed Web of Science ®Google Scholar
• Zhao Z-T, Ji CM, Yu WJ Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742–1750.e4. doi:10.1016/j.jaci.2015.12.134227040372
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma. Global strategy for asthma management and prevention; 2017 Available from: www.ginasthma.com. Accessed 809, 2019.
   Google Scholar
• Kaplan A, Ledford D, Ashby M. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132::101–109. doi:10.1016/j.jaci.2013.05.013
   Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh HJ. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935. doi:10.1056/NEJMoa121537223432142
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H 1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75. doi:10.1038/jid.2014.30625046337
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410–1416. doi:10.1016/j.rmed.2010.04.01320483574
   PubMed Web of Science ®Google Scholar
• Cherrez-Ojeda I, Maurer M, Bernstein JA. Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organ J. 2019;12:100011. doi:10.1016/j.waojou.2019.10001130937137
   PubMed Web of Science ®Google Scholar
• Košnik M, Kopač P, Eržen R. Omalizumab in chronic urticaria: our experience and literature review. Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:57–61. doi:10.15570/actaapa.2014.1425242162
   PubMedGoogle Scholar
• Cox L, Platts-Mills TA, Finegold Iet al. American academy of allergy, asthma & immunology.; american college of allergy, asthma and immunology. American academy of allergy, asthma &immunology/american college of allergy, asthma and immunology joint taskforce report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373e–1377e.17996286
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Stagnozzi G, Giuliodoro S. The safety of Omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C. Ann Allergy Asthma Immunol. 2009;103:269–270. doi:10.1016/S1081-1206(10)60194-919788028
   PubMed Web of Science ®Google Scholar
• Chicharro P, Rodríguez-Jiménez P, de Argila D. Efficacy and safety of omalizumab in a patient with chronic spontaneous urticaria and active hepatitis B virus infection. Actas Dermosifiliogr. 2017;108:383–384. doi:10.1016/j.ad.2016.10.00527914623
   PubMed Web of Science ®Google Scholar
• Leiva-Salinas M, Francés L, Marin‐Cabanas I. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J Eur Acad Dermatol Venereol. 2015;29:1027–1028. doi:10.1111/jdv.1266924629127
   PubMed Web of Science ®Google Scholar
• Gonçalves R, Valente C, Ferreira E, Serra JE, Da Cunha JS. Cytomegalic hepatitis in a patient receiving omalizumab. IDCases. 2016;5:83–84. doi:10.1016/j.idcr.2016.08.00127583207
   PubMedGoogle Scholar
• Odajima H, Ebisawa M, Nagakura T, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of Omalizumab in children with severe uncontrolled asthma. Allergology Int. 2017;66:106–115. doi:10.1016/j.alit.2016.06.004
   PubMed Web of Science ®Google Scholar
• Esquivel A, Busse WW, Calatroni A. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196:985–992. doi:10.1164/rccm.201701-0120OC28608756
   PubMed Web of Science ®Google Scholar
• Teach SJ, Kull S, Rennert S, et al. Preseasonal treatment with either Omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476–1485. doi:10.1016/j.jaci.2015.04.01026518090
   PubMed Web of Science ®Google Scholar
• Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with Omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37:197–207. doi:10.1111/cea.2007.37.issue-217250692
   PubMed Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of Omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60. doi:10.1016/j.rmed.2017.07.01329206634
   PubMed Web of Science ®Google Scholar
• Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139:1489–1495.e5. doi:10.1016/j.jaci.2016.07.03827639934
   PubMed Web of Science ®Google Scholar
• Chipps BE, Zeiger RS, Luskin AT. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119:524–532.e2. doi:10.1016/j.anai.2017.09.05629054589
   PubMed Web of Science ®Google Scholar
• Ali Z, Ulrik CS. Obesity and asthma: a coincidence or a causal relationship? A systematic review. Respir Med. 2013;107:1287–1300. doi:10.1016/j.rmed.2013.03.01923642708
   PubMed Web of Science ®Google Scholar
• Xu M, Xu J, Asthma YX. Risk of cardiovascular disease or all-cause mortality: a meta-analysis. Ann Saudi Med. 2017;37:99–105. doi:10.5144/0256-4947.2017.9928377538
   PubMed Web of Science ®Google Scholar
• Egeberg A, Kofoed K, Gislason G, Vestergaard C, Thyssen J. Cardiovascular risk is not increased in patients with chronic urticaria: a retrospective population-based cohort study. Acta Derm Venereol. 2017;97:261–262. doi:10.2340/00015555-251627535552
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without Omalizumab. J Allergy Clin Immunol. 2014;134:560–567.e4. doi:10.1016/j.jaci.2014.02.00724679845
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26. doi:10.1111/ijd.2017.56.issue-127337170
   PubMed Web of Science ®Google Scholar
• Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:1–7. doi:10.1155/2014/354250
   Google Scholar